Valuation : Recce Pharmaceuticals Ltd

Market Cap 113M 81.14M 69.78M 65.84M 59.98M 112M 7.76B 784M 302M 3.93B 305M 298M 12.5B P/E 2027 *
-4.35x
P/E 2028 * 3.33x
Enterprise Value 138M 99.04M 85.17M 80.36M 73.21M 137M 9.47B 957M 368M 4.8B 372M 364M 15.25B EV / Sales 2027 *
11.1x
EV / Sales 2028 * 1.2x
Free-Float
62.73%
Yield 2027 *
-
Yield 2028 * -
1 day+4.23%
1 week+2.78%
Current month-1.33%
1 month-1.33%
3 months-27.45%
6 months-13.95%
Current year-43.08%
1 week 0.34
Extreme 0.345
0.37
1 month 0.34
Extreme 0.345
0.38
Current year 0.34
Extreme 0.345
0.73
1 year 0.34
Extreme 0.345
0.73
3 years 0.28
Extreme 0.275
0.73
5 years 0.28
Extreme 0.275
1.38
10 years 0.13
Extreme 0.13
1.88
Manager TitleAgeSince
Chief Executive Officer - 28/08/2020
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - 30/09/2020
Director TitleAgeSince
Director/Board Member - 01/10/2012
Director/Board Member - 01/05/2012
Director/Board Member - 01/09/2022
Date Insider Type Main position Quantity % Market Cap. Importance
31/7/26 Buy

Chief Executive Officer

25,000 0.0083%
31/7/26 Buy

Director

75,000 0.0250%
31/7/26 Buy

Director

37,500 0.0125%
Change 5-day change 1-year change 3-year change Capi.($)
+4.23%+2.78%-22.92%-43.08% 78.27M
+0.08%-3.07%+48.95%+88.73% 1,002B
-0.31%-4.29%+51.60%+63.83% 644B
+1.33%-2.46%+19.93%+70.30% 443B
-0.63%-3.09%+29.84%+36.08% 343B
+0.43%-14.61%+11.32%+26.98% 262B
+0.93%-3.19%-1.31%+11.96% 245B
-2.20%-13.85%+37.38%+46.19% 212B
-0.90%-5.06%-18.47%-58.14% 199B
-0.61%-4.27%+25.61%+87.90% 181B
Average +0.41%-4.64%+18.19%+33.08% 352.98B
Weighted average by Cap. +0.12%-4.24%+31.97%+55.99%

Financials

2027 *2028 *
Net sales 12.5M 8.96M 7.71M 7.27M 6.62M 12.38M 857M 86.6M 33.33M 435M 33.65M 32.92M 1.38B 54.3M 38.94M 33.49M 31.6M 28.79M 53.81M 3.72B 376M 145M 1.89B 146M 143M 6B
Net income -25.1M -18M -15.48M -14.61M -13.31M -24.87M -1.72B -174M -66.95M -873M -67.59M -66.11M -2.77B 33.4M 23.95M 20.6M 19.44M 17.71M 33.1M 2.29B 231M 89.09M 1.16B 89.95M 87.98M 3.69B
Net Debt 24.96M 17.9M 15.4M 14.53M 13.23M 24.74M 1.71B 173M 66.59M 868M 67.23M 65.76M 2.76B -48.1M -34.5M -29.67M -27.99M -25.5M -47.67M -3.3B -333M -128M -1.67B -130M -127M -5.31B
Logo Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd is an Australia-based company. The Company is engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the processes utilized by bacteria and viruses to overcome resistance.
Employees
-
Date Price Change Volume
10/09/26 A$0.3700 +4.23% 97,134
09/09/26 A$0.3550 -4.05% 29,672
08/09/26 A$0.3700 +2.78% 242,532
07/09/26 A$0.3600 -2.70% 59,963
04/09/26 A$0.3700 +2.78% 75,875

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!